The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy
Open accessAbstract
Targeted delivery of RNA-based therapeutics for cancer therapy remains a challenge. We have developed a LPH (liposome-polycation-hyaluronic acid) nanoparticle formulation modified with tumor-targeting single-chain antibody fragment (scFv) for systemic delivery of small interfering RNA (siRNA) and microRNA (miRNA) into experimental lung metastasis of murine B16F10 melanoma. The siRNAs delivered by the scFv targeted nanoparticles efficiently downregulated the target genes (c-Myc/MDM2/VEGF) in the lung metastasis. Two daily intravenous injections of the combined siRNAs in the GC4-targeted nanoparticles significantly reduced the tumor load in the lung. miRNA-34a (miR-34a) induced apoptosis, inhibited survivin expression, and downregulated MAPK pathway in B16F10 cells. miR-34a delivered by the GC4-targeted nanoparticles significantly downregulated the survivin expression in the metastatic tumor and reduced tumor load in the lung. When miR-34a and siRNAs were co-formulated in GC4-targeted nanoparticles, an enhanced anticancer effect was observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,221
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells
Welch, C., Chen, Y., & Stallings, R. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210293 · Cited by 805
Self-citationMicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes
Li, Y., Guessous, F., Zhang, Y., DiPierro, C., Kefas, B., Johnson, E., Marcinkiewicz, L., Jiang, J., Yang, Y., Schmittgen, T. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0529 · Cited by 614
Li, N., Fu, H., Tie, Y., Hu, Z., Kong, W., Wu, Y., & Zheng, X. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.09.035 · Cited by 418
Tumor-targeted Delivery of siRNA by Self-assembled Nanoparticles
Li, S.-D., Chen, Y.-C., Hackett, M. J., & Huang, L. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300323 · Cited by 333
Self-citationFecher, L. A., Amaravadi, R. K., & Flaherty, K. T. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f5271c · Cited by 249
Chono, S., Li, S.-D., Conwell, C. C., & Huang, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.006 · Cited by 238
Self-citationYan, D., Zhou, X., Chen, X., Hu, D.-N., Dong, X. D., Wang, J., Lu, F., Tu, L., & Qu, J. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2681 · Cited by 211
Research works printed but not linked: 6
- Zhu, 2009, Identification of internalizing human single chain antibodies targeting brain tumor sphere cells, Mol Cancer Ther
- Xia, 2006, Construction of human ScFv phage display library against ovarian tumor, J Huazhong Univ Sci Technol Med Sci, 26, 497, 10.1007/s11596-006-0502-y · doi:10.1007/s11596-006-0502-y
- Tsantili, 1999, High affinity single-chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor, J Neuroimmunol, 94, 15, 10.1016/S0165-5728(98)00195-7 · doi:10.1016/s0165-5728(98)00195-7
- Chen, 2009, Enhancement of survivin gene downregulation and cell apoptosis by a novel combination: liposome microbubbles and ultrasound exposure, Med Oncol, 26, 491, 10.1007/s12032-008-9161-0 · doi:10.1007/s12032-008-9161-0
- Ruvkun, 2006, Clarifications on miRNA and cancer, Science, 311, 36, 10.1126/science.311.5757.36d · doi:10.1126/science.311.5757.36d
- Conrad, 2009, Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion, J Mol Med, 87, 507, 10.1007/s00109-009-0446-3 · doi:10.1007/s00109-009-0446-3
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Iorio, M. V., & Croce, C. M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100209 · Cited by 1,739
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Torchilin, V. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4333 · Cited by 1,663
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Kasinski, A. L., & Slack, F. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3166 · Cited by 936
miR-34 – a microRNA replacement therapy is headed to the clinic
Bader, A. G. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00120 · Cited by 728
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies
Chen, Y., Gao, D.-Y., & Huang, L. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.009 · Cited by 672
Self-citationZhang, Y., Wang, Z., & Gemeinhart, R. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.015 · Cited by 535
Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier
Upadhyay, R. K. (2014) · BioMed Research International · doi:10.1155/2014/869269 · Cited by 528
Mir-34: A New Weapon Against Cancer?
Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.47 · Cited by 498
Kievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496
Targeting long non-coding RNAs in cancers: Progress and prospects
Li, C. H., & Chen, Y. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.030 · Cited by 473
Self-citationMicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review
Catto, J. W. F., Alcaraz, A., Bjartell, A. S., De Vere White, R., Evans, C. P., Fussel, S., Hamdy, F. C., Kallioniemi, O., Mengual, L., Schlomm, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.01.044 · Cited by 469
Shu, D., Shu, Y., Haque, F., Abdelmawla, S., & Guo, P. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.105 · Cited by 435
Polysaccharide-based nanoparticles for theranostic nanomedicine
Swierczewska, M., Han, H. S., Kim, K., Park, J. H., & Lee, S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.015 · Cited by 415
MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma
Ibrahim, A. F., Weirauch, U., Thomas, M., Grünweller, A., Hartmann, R. K., & Aigner, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4645 · Cited by 400
Gandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 385
Liposomal Delivery Systems: Design Optimization and Current Applications
Abu Lila, A. S., & Ishida, T. (2017) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00624 · Cited by 382
Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.012 · Cited by 380
In Vivo Gene Delivery by Nonviral Vectors: Overcoming Hurdles?
Zhang, Y., Satterlee, A., & Huang, L. (2012) · Molecular Therapy · doi:10.1038/mt.2012.79 · Cited by 349
Self-citationNon-coding RNAs and potential therapeutic targeting in cancer
Toden, S., Zumwalt, T. J., & Goel, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188491 · Cited by 327
Treating cancer with microRNA replacement therapy: A literature review
Hosseinahli, N., Aghapour, M., Duijf, P. H. G., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26514 · Cited by 305
Cho, H.-J., Yoon, H. Y., Koo, H., Ko, S.-H., Shim, J.-S., Lee, J.-H., Kim, K., Chan Kwon, I., & Kim, D.-D. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.06.028 · Cited by 304
Baumann, V., & Winkler, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.116 · Cited by 297
Delivering the promise of miRNA cancer therapeutics
Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. P. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.002 · Cited by 288
Fu, Q.-F., Liu, Y., Fan, Y., Hua, S.-N., Qu, H.-Y., Dong, S.-W., Li, R.-L., Zhao, M.-Y., Zhen, Y., Yu, X.-L., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0117-5 · Cited by 286
Self-citationConde, J., Oliva, N., Atilano, M., Song, H. S., & Artzi, N. (2016) · Nature Materials · doi:10.1038/nmat4497 · Cited by 283
Jansen, F., Nickenig, G., & Werner, N. (2017) · Circulation Research · doi:10.1161/circresaha.117.310752 · Cited by 280
MicroRNA Therapeutics: the Next Magic Bullet?
Simonson, B., & Das, S. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150324123208 · Cited by 263
MicroRNA replacement therapy in cancer
Mollaei, H., Safaralizadeh, R., & Rostami, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28058 · Cited by 262
Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Agostini, M., & Knight, R. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1825 · Cited by 254
pH-sensitive biomaterials for drug delivery
Zhuo, S., Zhang, F., Yu, J., Zhang, X., Yang, G., & Liu, X. (2020) · Molecules · doi:10.3390/molecules25235649 · Cited by 247
Self-citationIn vivo delivery of RNAi with lipid-based nanoparticles
Huang, L., & Liu, Y. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124709 · Cited by 174
Self-citationAll’s well that transcribes well: Non-coding RNAs and post-stroke brain damage
Vemuganti, R. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.07.014 · Cited by 71
Mafi, A., Rahmati, A., Babaei Aghdam, Z., Salami, R., Salami, M., Vakili, O., & Aghadavod, E. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00354-4 · Cited by 56
Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors
Iyer, A. K., Duan, Z., & Amiji, M. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500024p · Cited by 55
Metadata
- Authors
- Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 18
- Issue
- 9
- Pages
- 1650-1656
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1972461780
- Cited by
- 515
- References
- 22
- FWCI
- 16.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 2228 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.